Stockholm3 outperforms other prostate cancer biomarkers and risk calculators
Prenumeration
A recently published article in the Journal of Urology highlights the effectiveness of Stockholm3 in improving prostate cancer detection. The clinical study utilized the diverse American SEPTA cohort to demonstrate superior performance of Stockholm3 to commonly used biomarkers and risk calculators.
“The original results of the SEPTA trial showed that nearly half of unnecessary biopsies could be avoided by using Stockholm3 compared to PSA, with equivalent performance across racial and ethnic groups. The results from the new study show that outcomes are similar even when using additional biomarkers like free to total PSA ratio,” says senior author Scott Eggener, Professor of Surgery at the University of Chicago.
Stockholm3 has been developed in a population-based screening setting and validated in Europe and the U.S. The landmark SEPTA trial was a validation of Stockholm3 in a multi-ethnic cohort published in the Journal of Clinical Oncology in 2024 (1). The trial involved over 2,000 racially and ethnically diverse men recruited in the U.S. and Canada, whereof more than 1,100 represented Asian, Black and Hispanic minorities, who met local standards of care to undergo a prostate biopsy.
The recently published follow-up study shows that Stockholm3 outperforms free to total PSA ratio, PSA density, and contemporary risk calculators including the European Randomized Study of Screening for Prostate Cancer-4 calculator, the Prostate Biopsy Collaborative Group calculator, and the Prostate Cancer Prevention Trial version 2 calculator (2). Compared to clinically used thresholds of a free to total PSA ratio, Stockholm3 could reduce unnecessary biopsies by 44% with 95% sensitivity.
(1) Vigneswaran HT, Eklund M, Discacciati A, Nordström T, Hubbard RA, Perlis N, Abern MR, Moreira DM, Eggener S, Yonover P, Chow AK, Watts K, Liss MA, Thoreson GR, Abreu AL, Sonn GA, Palsdottir T, Plym A, Wiklund F, Grönberg H, Murphy AB; SEPTA STHLM3 Study Group. Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. J Clin Oncol. 2024 Nov 10;42(32):3806-3816. doi: 10.1200/JCO.24.00152. Epub 2024 Jul 22. PMID: 39038251.
(2) Lazarovich A, Vigneswaran H, Palsdottir T, Eklund M, Discacciati A, Nordström T, Hubbard RA, Perlis N, Abern MR, Moreira DM, Yonover P, Chow AK, Watts K, Liss MA, Thoreson GR, Abreu AL, Sonn GA, Plym A, Wiklund F, Grönberg H, Murphy AB, Eggener S. A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial. J Urol. 2025 May;213(5):590-599. doi: 10.1097/JU.0000000000004437. Epub 2025 Apr 9. PMID: 40202133.